Generation of an induced pluripotent stem cell (iPSC) line (JUCTCi017-A) from a patient with limb-girdle muscular dystrophy (LGMD) due to a homozygous p.Lue287Ser fs14* mutation in the SGCB gene

Nidaa A. Ababneh(University of Jordan), Abdalla Awidi(University of Jordan), Mohammad H. Gharandouq(University of Jordan), Nour Sharar(Hamad bin Khalifa University), Hebah Alshahwan(University of Jordan), Leena N. Alnsour(Jordan Hospital), Leen Makahleh(University of Jordan), Suzan Zalloum(University of Jordan), Renata M. Alatoom(University of Jordan), Dema Ali(University of Jordan), Raghda Barham(University of Jordan), Mohammed El-Khateeb, Ban Al-Kurdi(University of Jordan)
Stem Cell Research
May 11, 2021
10.1016/j.scr.2021.102358
Cited by 0

Related Papers

siRNA: Mechanism of action, challenges, and therapeutic approaches
|European Journal of Pharmacology|2021|428
<i>C9orf72</i> Hexanucleotide Expansions Are Associated with Altered Endoplasmic Reticulum Calcium Homeostasis and Stress Granule Formation in Induced Pluripotent Stem Cell-Derived Neurons from Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
|Stem Cells|2016|248
Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: a phase I/II study
|Journal of Orthopaedic Surgery and Research|2017|141
Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy
|CNS Neuroscience & Therapeutics|2017|123
Safety and Potential Therapeutic Effect of Two Intracavernous Autologous Bone Marrow Derived Mesenchymal Stem Cells injections in Diabetic Patients with Erectile Dysfunction: An Open Label Phase I Clinical Trial
|Urologia Internationalis|2018|109